Cover Image

Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations

Background: Small molecule receptor antagonists (gepants), or monoclonal antibodies (mAbs) against calcitonin gene-related peptide (CGRP) have recently become available for migraine prophylaxis and/or acute treatment. Considering their shared mechanisms of action, if the failure to an anti-CGRP(R) m...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrea Burgalassi (Author), Giulia Vigani (Author), Alberto Boccalini (Author), Francesco De Cesaris (Author), Guido Mannaioni (Author), Alberto Chiarugi (Author), Pierangelo Geppetti (Author), Luigi Francesco Iannone (Author)
Format:	Book
Published:	SAGE Publishing, 2024-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of rimegepant as an alternative to triptans in migraine treatment
by: Aleksandra Jaroń, et al.
Published: (2024)

Antagonism of CGRP Signaling by Rimegepant at Two Receptors
by: Kylie S. Pan, et al.
Published: (2020)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
by: Bianca Raffaelli, et al.
Published: (2023)

Triptans do not Increase Risk of Stroke in Migraine
by: J Gordon Millichap
Published: (2004)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023)

Efficient and Scalable Enantioselective Synthesis of a Key Intermediate for Rimegepant: An Oral CGRP Receptor Antagonist
by: Zhonghua Luo, et al.
Published: (2024)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019)

Rimegepant - a breakthrough drug for migraine treatment - literature review
by: Katarzyna Kuleta, et al.
Published: (2024)

Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study
by: Reem Suliman, et al.
Published: (2024)

Triptan-Withdrawal Headache
by: J Gordon Millichap
Published: (2001)

Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan
by: Yasushi Shibata, et al.
Published: (2024)

Effect of Xiongmatang Extract on Behavioral and TRPV1-CGRP/CGRP-R Pathway in Rats With Migraine
by: Dingding Liu, et al.
Published: (2022)

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
by: Bixi Gao, et al.
Published: (2020)

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
by: Ronan Mahon, et al.
Published: (2024)

5-HT1 receptor inhibitors (triptans) for the treatment of migraine during pregnancy: an analysis of the instructions for medical use
by: Y. O. Hrynkiv
Published: (2022)

Efficacy and safety of anti-CGRP monoclonal antibodies for chronic migraine prophylaxis in patients treated with botulinum toxin A: A prospective monocentric study
by: Calogera Butera, et al.
Published: (2024)

Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
by: Danuta Szkutnik-Fiedler
Published: (2020)

Effects of Anti-CGRP Monoclonal Antibodies on Neurophysiological and Clinical Outcomes: A Combined Transcranial Magnetic Stimulation and Algometer Study
by: Paolo Manganotti, et al.
Published: (2024)

Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study
by: Gilbert L'Italien, et al.
Published: (2022)

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
by: Eric R Ocheretyaner, et al.
Published: (2022)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments-New Therapeutic Technologies for Migraine
by: Linda Sangalli, et al.
Published: (2023)

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
by: Ja Bin Hong, et al.
Published: (2023)

Constipation as a possible predictor of poor treatment response in chronic migraine: A retrospective study of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies and the impact of switching
by: Sena Uzun, et al.
Published: (2024)

Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine
by: David Moreno-Ajona, et al.
Published: (2020)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023)

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis
by: Casper Emil Christensen, et al.
Published: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
by: David Monteith, et al.
Published: (2017)

Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
by: Aqfan Jamaluddin, et al.
Published: (2022)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?
by: Theodoros Mavridis, et al.
Published: (2021)

The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats
by: Fang Wang, et al.
Published: (2021)

Tolerability of calcitonin gene-related peptide monoclonal antibodies and other monoclonal antibodies in adults with concurrent migraine and other medical conditions
by: Kevin Weber, et al.
Published: (2024)

The impact of topiramate, botulinum toxin type A, and CGRP-antibodies on medication overuse headache in patients with chronic migraine: A protocol for systematic review and meta-analysis
by: Samita Giri, et al.
Published: (2022)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020)

Refractory thrombotic thrombocytopenic purpura treated successfully with monoclonal antibody (rituximab)
by: B Saroj Kumar Prusty, et al.
Published: (2023)

CGRP Is Critical for Hot Flushes in Ovariectomized Mice
by: Daniel B. Wilhelms, et al.
Published: (2019)

Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
by: Keisuke Suzuki, et al.
Published: (2024)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
by: Carine M. Lama, MS, et al.
Published: (2023)

Treatment of refractory prurigo nodularis with a monoclonal antibody dupilumab with surprising clinical response
by: Juliana P Alves, et al.
Published: (2023)

Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison
by: María del Pilar Briceño-Casado, et al.
Published: (2020)